Anti-Inflammatory Biologics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, and Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030

The anti-inflammatory biologics market size was valued at USD 93.13 billion in 2022 and is projected to grow from USD 93.32 billion in 2023 to USD 139.80 billion by 2030, exhibiting a CAGR of 5.9% during the forecast period. Moreover, the U.S. anti-inflammatory biologics market size is projected to grow significantly, reaching an estimated value of USD 77.46 billion by 2030, driven by increase in demand for anti-inflammatory bilogics due to surge in inflammatory disease incidence.

Anti-inflammatory biologics is an emerging treatment for autoimmune inflammatory diseases. The prevalence of inflammatory diseases, such as psoriasis, ulcerative colitis, rheumatoid arthritis, and inflammatory bowel diseases is increasing and so is the demand for biologics. Continuous research on anti-Tumor Necrosis Factor (TNF), interleukin antagonists, Janus Kinase (JAK) inhibitors are adding to the number of potential drug candidates waiting for approval or in the clinical stage.

COVID-19 IMPACT

COVID-19 Positively Affected Market Revenue Due to High Sales of the Biologics

The COVID-19 pandemic is anticipated to positively impact the anti-inflammatory therapeutics market due to the severe inflammation induced by SARS-CoV-2. The coronavirus triggers anti-inflammatory pneumonia, particularly in severe COVID-19 cases.

The increased awareness of inflammation's role has spurred increased research and development, leading to the repurposing of existing anti-inflammatory drugs and the development of novel treatments. Market players operating in the market have experienced a growth in their biologics revenue in 2020 compared to 2019 due to the increased adoption of biologics during the pandemic.

• For instance, in 2020, Regeneron Pharmaceuticals Inc. generated a revenue of USD 270.0 million for its drug, Kevzara, experiencing a growth of 39.0% compared to 2021.

Furthermore, the pandemic's influence on healthcare delivery has extended to the adoption of telemedicine. This shift has positively impacted this market by improving patient access to treatments.

In 2021 & 2022, the market is expected to grow at a slower pace compared to 2020. Furthermore, the loss of patent protection for various biologics is another reason for the slower growth of the market in 2021 & 2022.

Anti-Inflammatory Biologics Market Trends

Transition from Anti-Tumor Necrosis Factor (TNF) to Non-Anti-Tumor Necrosis Factor (TNF) to Treat Inflammatory Diseases

In recent years, patients of inflammatory diseases have stopped responding to anti-TNF treatments and are going for non-anti TNF therapies, such as Janus Kinase (JAK) and interleukin inhibitors. The transition is attributed to the various benefits associated with Non-Anti-Tumor Necrosis Factor.

The JAK inhibitors offer a novel mechanism of action, targeting the Janus Kinase pathway involved in the regulation of the immune response. This provides an alternative therapeutic approach for patients who do not respond adequately to TNF inhibitors or experience adverse effects.

Furthermore, the convenience of oral administration with JAK inhibitors as compared to that of injectable TNF inhibitors appeals to both patients and healthcare providers. This ease of use enhances patient adherence and overall treatment compliance.

The market players are also focusing on the development of these Non-Anti-Tumor Necrosis Factors. This has created a large volume of clinical evidence supporting the effectiveness and safety of JAK inhibitors and interleukin inhibitors, which is increasing their adoption.

Anti-Inflammatory Biologics Market Growth Factors

Rising Prevalence of Inflammatory Diseases to Favor Market Growth

Increasing prevalence of autoimmune inflammatory diseases, such as psoriasis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, ulcerative colitis, and others is a major factor driving the market growth. For instance, according to a study published by the NCBI in August 2021, the prevalence of psoriasis in adults aged 20 years or older was 3% in the U.S. This factor is anticipated to foster the market progress during the forecast period. In addition to this, the rapid adoption of biologics for the treatment of inflammatory diseases as well as favorable reimbursement for biological therapies is expected to favor the market growth.

Increasing Number of Potential Pipeline Candidates to Boost Market Development

Many pharmaceutical giants are actively investing in research activities for the development of biologics. This has led to an increased presence of potential drug candidates in clinical trials. The expected launch of these potential pipeline candidates is projected to provide a significant boost to the market growth. With the advent of monoclonal antibodies and technological advancements, novel biological therapies can be developed to have anti-inflammatory action. For example, in December 2019, UCB S.A. announced positive results from the phase 3 clinical study of Bimekizumab for the treatment of psoriasis. Apart from this, research to expand the application of existing biologics to other rare anti-inflammatory diseases, such as lupus, diffuse systemic sclerosis, and others is likely to augment the adoption of anti-inflammatory biologics.

RESTRAINING FACTORS

Lack of Inclination for Biologics as First Line of Treatment to Restrict Market Growth

Despite anti-inflammatory biologics being highly effective in the treatment of psoriasis and rheumatoid arthritis, lack of preference for them, and growing inclination toward Disease-Modifying Anti-Rheumatic Drugs (DMARDs) are the key reasons for hampering the market growth. DMARDs, such as methotrexate is used as the first line of treatment for rheumatoid arthritis. Similarly, in the case of psoriasis, topical drugs, such as corticosteroids and vitamin D analogues are used as the first line of treatment. In comparison, anti-inflammatory biologics are used as the third line of treatment for both the diseases. This factor is expected to reduce the patient pool for these drugs, in turn negatively impacting the market growth.

Anti-Inflammatory Biologics Market Segmentation Analysis

By Drug Class Analysis

Interleukin Antagonist accounted for the Largest Share owing to Increase Prevalence of Inflammatory Condition

Based on drug class, the market is segmented into Anti-Tumor Necrosis Factor (TNF), interleukin antagonists, Janus Kinase (JAK) inhibitors, others.

Interleukin Antagonist held the largest share in the market in 2022. The growth is attributed to its efficacy in treating inflammatory conditions, growing patient preference for targeted therapies, and continuous research and development to introduce the novel drugs.

The Anti-Tumor Necrosis Factor (TNF) segment accounted for a substantial anti-inflammatory biologics market share in 2022. The segment’s growth can be attributed to the robust sales of Humira and rising prevalence of inflammatory bowel disease and other related diseases. Furthermore, the segment is expected to benefit from the high sales of drugs, such as Remicade as they are approved for treating a broader category of inflammatory diseases as compared to other drug classes, which are approved for limited disease indications.

The Janus Kinase (JAK) inhibitors segment is gradually gaining the market share owing to increased research activities and new product launches.

• For instance, in December 2021, AbbVie announced that the U.S. FDA had approved RINVOQ for the treatment of adults suffering from active Psoriatic Arthritis (PsA). A significant increase in the revenue of RINVOQ is expected to fuel the JAK inhibitors segment growth.

Furthermore, the segment is poised to expand owing to the rising prevalence of rheumatoid arthritis and growing adoption of monoclonal antibodies.

By Application Analysis

Other Applications Gained a Major Traction Due to Growing Prevalence of Chronic Diseases

Based on application, the market is segmented into rheumatoid arthritis, psoriasis, and others.

In 2022, the others segment held the highest market share owing to significant research investments, strategic partnerships, and new product launches. Other factors responsible for the expansion of this segment include the presence of potential pipeline candidates and increasing incidence of ulcerative colitis, Crohn’s disease, and ankylosing spondylitis.

The rheumatoid arthritis segment generated substantial revenue in 2022. Primary reasons for the growth of the segment are the rising prevalence of rheumatoid arthritis and availability of more anti-inflammatory biologics for this disease.

• According to the U.S. Centers for Disease Control and Prevention, 78 million adults in the U.S. are estimated to have doctor-diagnosed arthritis by 2040. This is estimated to further fuel the segment’s growth.

By Route of Administration Analysis

Injection to Become Primary Route of Administration Owing to Presence of Key Products

On the basis of route of administration, the market is segmented into oral and injection. The injection segment can be further bifurcated into subcutaneous and intravenous.

The injection segment is estimated to dominate the market throughout the forecast period. A vast majority of the anti-inflammatory biologics are administrated via the subcutaneous or intravenous route, which is the primary reason for the dominance of this segment.

The oral segment is anticipated to record a substantial CAGR owing to the market players’ increased focus on introducing oral biologics and higher sales of products, such as Xeljanz (tofacitinib) and Otezla (apremilast).

By Distribution Channel Analysis

Hospital Pharmacy Emerged as a Primary Distribution Channel Due to High Patient Volumes in Hospitals

In terms of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

The hospital pharmacy segment generated the maximum revenue in 2022, which can be attributed to the increasing adoption of monoclonal antibodies, rising prevalence of inflammatory diseases, and favorable health reimbursement policies.

The retail pharmacy segment is poised to grow steadily due to the increasing number of pharmacies and rising prescriptions for biologics. The online pharmacy segment is likely to grow at a healthy pace owing to increasing disposable income, active government support, and rapid adoption of e-commerce platforms.

REGIONAL INSIGHTS

The market size in North America, holding the largest regional share, was valued at USD 59.37 billion in 2022. Significant increase in the demand for anti-TNF drugs and potential pipeline candidates are the primary factors accelerating the growth of the market in North America. Moreover, strategic position of key the players and high sales of their drugs in the region are estimated to augment the market’s expansion in North America.

Europe held the second-highest market share in 2022 and is anticipated to record a substantial CAGR during the forecast period. Significant R&D investments and increasing focus of market players on the introduction of new drugs in the region are expected to boost the demand for anti-inflammatory biologics during the forecast timeframe.

The market in Asia Pacific is predicted to record the fastest CAGR during the forecast period. The market’s growth in the region is attributed to the rising prevalence of various inflammatory disorders and growing awareness regarding the treatment options available for these diseases.

In Latin America and the Middle East & Africa, the market is projected to grow due to the huge unmet needs of the patient population, improving healthcare reforms, and rising disposable income.

List of Key Anti-Inflammatory Biologics Market Companies

AbbVie Accounted for Leading Market Share Owing to Presence of Key Products in Its Portfolio

In terms of market revenue, AbbVie accounted for the leading position in the market. Higher sales of Humira, significant research investments, and established market presence are the factors responsible for the dominant share of the company in the market. Moreover, AbbVie is continuously focusing on the introduction of advanced drugs in the drug class other than Anti-Tumor Necrosis Factor (TNF), which is expected to increase its revenue in the market in the future.

Furthermore, market players, such as Pfizer Inc. Amgen Inc., Biogen, UCB S.A., and others are also having a prominent position in the market due to their high focus on the development of novel drugs. Additionally, these companies are focusing on obtaining the regulatory approvals for their drugs by reputed agencies, such as the U.S. FDA to treat inflammatory diseases.

LIST OF KEY COMPANIES PROFILED:

• AbbVie Inc. (U.S.)


• Merck & Co., Inc. (U.S.)


• Bristol-Myers Squibb Company (U.S.)


• Johnson & Johnson Services, Inc. (U.S.)


• Pfizer Inc. (U.S.)


• Novartis AG (Switzerland)


• UCB S.A. (Belgium)


• Eli Lilly and Company (U.S.)


• Amgen Inc. (U.S.)


• Biogen (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• February 2023 - Pfizer Inc. announced the approval of its supplemental New Drug Application (sNDA) for CIBINQO by the U.S. FDA for patients suffering from moderate-to-severe atopic dermatitis.


• March 2022 - AbbVie announced the U.S. FDA’s approval of RINVOQ (upadacitinib) for the treatment of adults suffering from ulcerative colitis.


• October 2022 - GSK plc provided an update on the ContRAst phase III program for otilimab, an investigational monoclonal antibody used in the potential treatment of moderate to severe rheumatoid arthritis.


• September 2022 - Bristol Myers Squibb announced two-year results from the POETYK PSO Long-Term Extension (LTE) trial with continuous Sotyktu treatment in adult patients diagnosed with plaque psoriasis.


• December 2021: Pfizer Inc. announced the approval of Cibinqo (abrocitinib), an oral, once-daily, Janus Kinase 1 (JAK1) inhibitor, for the treatment of Atopic Dermatitis (AD) by the European Commission (EC).

REPORT COVERAGE

The global anti-inflammatory biologics market report offers a detailed analysis of various factors affecting the market. These include growth drivers, restraints, opportunities, threats, and key industry developments. In addition to this, the report helps in analyzing, segmenting, and defining the market based on different segments, such as drug class, application, route of administration, and distribution channel. It also provides various prominent insights, such as prevalence of psoriasis and rheumatoid arthritis in key countries, patent snapshot, pipeline analysis, new product launches, key mergers & acquisitions, joint ventures, and COVID-19 impact.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 5.9% from 2023-2030
Unit	Value (USD billion)
Segmentation	By Drug Class Anti-Tumor Necrosis Factor (TNF) Interleukins Antagonists Janus Kinase (JAK) Inhibitors Others
By Application Rheumatoid Arthritis Psoriasis Others
By Route of Administration Oral Injection Intravenous Subcutaneous
By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Geography North America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country) U.S. Canada Europe (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region) U.K. Germany France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region) Japan China India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region) GCC South Africa Rest of Middle East & Africa